| Q37612692 | A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance |
| Q38942616 | A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors |
| Q37564708 | Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options |
| Q90475067 | Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer |
| Q36918202 | Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer |
| Q38775432 | Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents |
| Q38012499 | Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. |
| Q91953697 | Dynamic changes in histone deacetylases following kidney ischemia-reperfusion injury are critical for promoting proximal tubule proliferation |
| Q38230244 | Emerging role of epigenetics in systemic sclerosis pathogenesis. |
| Q38674317 | Entinostat for the treatment of breast cancer. |
| Q33838633 | Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. |
| Q38906418 | Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents |
| Q39220891 | Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment |
| Q34431964 | Epigenetic drugs against cancer: an evolving landscape |
| Q37150340 | Epigenetic mechanisms in cerebral ischemia. |
| Q26823070 | Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges |
| Q28067666 | Epigenetic polypharmacology: from combination therapy to multitargeted drugs |
| Q35014402 | Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat |
| Q58130496 | Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types |
| Q34541756 | Epigenetic susceptibility factors for prostate cancer with aging. |
| Q37707110 | Epigenetic therapy in urologic cancers: an update on clinical trials. |
| Q26773803 | Epigenetic treatment of solid tumours: a review of clinical trials |
| Q33801377 | Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects |
| Q88985337 | Epigenetics in renal cell cancer: mechanisms and clinical applications |
| Q91987605 | Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors |
| Q37578338 | Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay |
| Q38058971 | HDAC inhibitor-based therapies: can we interpret the code? |
| Q37115414 | HDAC inhibitors in kidney development and disease |
| Q38762886 | HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells |
| Q96950422 | Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin |
| Q95853354 | Histone Deacetylase Inhibitors: A Prospect in Drug Discovery |
| Q41664067 | Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises |
| Q36202684 | Histone acetylation regulates prostate ductal morphogenesis through a bone morphogenetic protein-dependent mechanism |
| Q38857969 | Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer |
| Q27025984 | Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma |
| Q38595978 | Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies |
| Q35214924 | Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents |
| Q46444003 | Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). |
| Q38572855 | Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review |
| Q37706134 | In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma |
| Q36906792 | In vivo organ specific drug delivery with implantable peristaltic pumps. |
| Q59804079 | Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer |
| Q36946516 | Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. |
| Q64099701 | Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model |
| Q64119454 | Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes |
| Q36745391 | Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment |
| Q38104670 | Molecular-targeted agents combination therapy for cancer: developments and potentials |
| Q26799714 | Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies |
| Q26771601 | Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? |
| Q28485252 | Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo |
| Q98938413 | Retinoic acid receptor γ is a therapeutically targetable driver of growth and survival in prostate cancer |
| Q58728553 | Retinoic acid signaling balances adult distal lung epithelial progenitor cell growth and differentiation |
| Q42680055 | Scaffold dependent histone deacetylase (HDAC) inhibitor induced re-equilibration of the subcellular localization and post-translational modification state of class I HDACs |
| Q55485574 | Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. |
| Q37325233 | Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model |
| Q58792448 | The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease |
| Q28533258 | The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2 |
| Q44397464 | The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced permeability transition and bioenergetic dysfunction of liver mitochondria: comparison with tamoxifen. |
| Q38095611 | The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers |
| Q91014017 | The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression |
| Q53156735 | The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. |
| Q26866044 | The roles of retinoic acid and retinoic acid receptors in inducing epigenetic changes |
| Q38924992 | Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells |
| Q40239307 | Treatment with Entinostat Heals Experimental Cholera by Affecting Physical and Chemical Barrier Functions of Intestinal Epithelia |
| Q50660192 | Vitamin A deficiency impairs spatial learning and memory: the mechanism of abnormal CBP-dependent histone acetylation regulated by retinoic acid receptor alpha. |
| Q38633074 | Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications |